CN106794229B - 工程化嵌合聚乙二醇化adi和使用方法 - Google Patents

工程化嵌合聚乙二醇化adi和使用方法 Download PDF

Info

Publication number
CN106794229B
CN106794229B CN201580022377.XA CN201580022377A CN106794229B CN 106794229 B CN106794229 B CN 106794229B CN 201580022377 A CN201580022377 A CN 201580022377A CN 106794229 B CN106794229 B CN 106794229B
Authority
CN
China
Prior art keywords
leu
glu
val
ile
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580022377.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN106794229A (zh
Inventor
B-W·吴
R·阿尔玛西
何玮
R·E·肖沃尔特
何娇娟
郭云云
J·A·汤姆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polaris Pharmaceutical Group Co ltd
Original Assignee
Tdw Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tdw Group filed Critical Tdw Group
Publication of CN106794229A publication Critical patent/CN106794229A/zh
Application granted granted Critical
Publication of CN106794229B publication Critical patent/CN106794229B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580022377.XA 2014-03-18 2015-03-18 工程化嵌合聚乙二醇化adi和使用方法 Active CN106794229B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461954929P 2014-03-18 2014-03-18
US61/954,929 2014-03-18
PCT/US2015/021189 WO2015143006A1 (en) 2014-03-18 2015-03-18 Engineered chimeric pegylated adi and methods of use

Publications (2)

Publication Number Publication Date
CN106794229A CN106794229A (zh) 2017-05-31
CN106794229B true CN106794229B (zh) 2020-12-18

Family

ID=54145261

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580022377.XA Active CN106794229B (zh) 2014-03-18 2015-03-18 工程化嵌合聚乙二醇化adi和使用方法

Country Status (7)

Country Link
US (1) US10463721B2 (https=)
EP (1) EP3119421B1 (https=)
JP (1) JP6612316B2 (https=)
KR (2) KR102523031B1 (https=)
CN (1) CN106794229B (https=)
SG (1) SG11201607736UA (https=)
WO (1) WO2015143006A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151982A2 (en) 2013-03-15 2014-09-25 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
WO2015143006A1 (en) 2014-03-18 2015-09-24 Tdw Group Engineered chimeric pegylated adi and methods of use
EP4104853B1 (en) 2014-09-16 2026-05-06 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
CN119950689A (zh) 2016-07-05 2025-05-09 北极星药业集团股份有限公司 使用精氨酸耗竭剂的组合癌症免疫疗法
TWI784982B (zh) * 2016-11-02 2022-12-01 開曼群島商北極星藥業集團股份有限公司 聚乙二醇化精胺酸脫亞胺酶之調配物
CN106591270B (zh) * 2017-01-23 2018-09-21 江南大学 一株定点突变改造的基因工程精氨酸脱亚胺酶
WO2018183671A1 (en) 2017-03-29 2018-10-04 Tdw Group Protein conjugates
US12508306B2 (en) 2018-04-25 2025-12-30 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
WO2022063178A1 (en) * 2020-09-23 2022-03-31 The Hong Kong Polytechnic University Fluorescent biosensor for rapid determination of l-arginine
KR102640230B1 (ko) * 2021-09-24 2024-02-22 가천대학교 산학협력단 C-peptide를 처리한 자궁내막 기질세포의 이동성 변화 기작을 이용한 자궁내막 관련질환의 진단 방법 및 자궁내막 관련질환 치료제의 스크리닝 방법
US20240084282A1 (en) * 2022-09-02 2024-03-14 Polaris Group Modified arginine deiminases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132713A (en) * 1997-01-31 2000-10-17 Enzon, Inc. Arginine deiminase derived from mycoplasma arthritidis and polymer conjugates containing the same
CN1518595A (zh) * 2000-11-28 2004-08-04 凤凰药理学公司 修饰的精氨酸脱亚胺酶
WO2005052145A2 (en) * 2003-10-07 2005-06-09 University Of Florida Recombinant alkaliizing bacteria
US20140348814A1 (en) * 2013-03-15 2014-11-27 Polaris Group Arginne deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
US5372942A (en) 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US6635462B1 (en) 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
US6180387B1 (en) * 1997-08-11 2001-01-30 Smithkline Beecham Corporation Arginine deiminase
IT1298918B1 (it) 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
WO2002009741A1 (en) 2000-07-27 2002-02-07 Angiolab, Inc. The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
WO2004046309A2 (en) 2002-11-18 2004-06-03 Phoenix Pharmacologics, Inc. Methods for inhibiting viral replication in vivo
EP1629119A2 (en) 2003-04-29 2006-03-01 Wyeth Methods for diagnosing aml and mds by differential gene expression
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
US20100197944A1 (en) 2007-07-04 2010-08-05 Dr. Reddy's Laboratories Limited Docetaxel process and polymorphs
US20090238813A1 (en) 2007-12-28 2009-09-24 Board Of Regents, The University Of Texas System Compositions And Methods For Engineered Human Arginine Deiminases
US20120015049A1 (en) 2009-01-14 2012-01-19 Lin Zhang Microrna biomarker in cancer
WO2011053871A2 (en) 2009-10-30 2011-05-05 Life Technologies Corporation Multi-primer assay for mycoplasma detection
JP2013527223A (ja) 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
US8663967B2 (en) 2011-08-22 2014-03-04 Jiangsu T-Mab Biopharma Co., Ltd. Arginine deiminase mutant and preparation and application thereof
EP2834262B1 (en) 2012-04-04 2020-09-02 Polaris Group Composition comprising pegylated arginine deiminase
WO2015143006A1 (en) 2014-03-18 2015-09-24 Tdw Group Engineered chimeric pegylated adi and methods of use
EP4104853B1 (en) 2014-09-16 2026-05-06 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132713A (en) * 1997-01-31 2000-10-17 Enzon, Inc. Arginine deiminase derived from mycoplasma arthritidis and polymer conjugates containing the same
CN1518595A (zh) * 2000-11-28 2004-08-04 凤凰药理学公司 修饰的精氨酸脱亚胺酶
WO2005052145A2 (en) * 2003-10-07 2005-06-09 University Of Florida Recombinant alkaliizing bacteria
US20140348814A1 (en) * 2013-03-15 2014-11-27 Polaris Group Arginne deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Crystal Structures of Arginine Deiminase with Covalent Reaction Intermediates: Implications for Catalytic Mechanism;Kalyan Das,et al;《Structure》;20040430;第12卷;657-667页 *
Structure-Informed Design of an Enzymatically Inactive Vaccine Component for Group A Streptococcus;Anna Henningham,et al;《mBio》;20130806;第4卷(第4期);1-9页 *

Also Published As

Publication number Publication date
JP6612316B2 (ja) 2019-11-27
WO2015143006A1 (en) 2015-09-24
KR102523031B1 (ko) 2023-04-19
US10463721B2 (en) 2019-11-05
KR20160134789A (ko) 2016-11-23
KR20220011806A (ko) 2022-01-28
CN106794229A (zh) 2017-05-31
EP3119421A1 (en) 2017-01-25
SG11201607736UA (en) 2016-10-28
KR102353046B1 (ko) 2022-01-19
JP2017513516A (ja) 2017-06-01
EP3119421B1 (en) 2019-10-02
US20170000862A1 (en) 2017-01-05
EP3119421A4 (en) 2017-11-29

Similar Documents

Publication Publication Date Title
CN106794229B (zh) 工程化嵌合聚乙二醇化adi和使用方法
TWI708612B (zh) 用於治療癌症之與 adi-peg 20 抗體具有降低之交叉反應性的精胺酸脫亞胺酶
KR102455753B1 (ko) 암치료를 위한 ａｄｉ-ｐｅｇ 20 항체에 대해 감소된 교차반응성을 지니는 아르기닌 탈이민효소
TWI699210B (zh) 工程化之嵌合聚乙二醇化ａｄｉ及使用方法
TWI676683B (zh) 用於癌症治療之對ａｄｉ－ｐｅｇ２０抗體交叉反應性降低之精胺酸去亞胺酶
HK1227767A1 (en) Engineered chimeric pegylated adi and methods of use
HK1227767B (en) Engineered chimeric pegylated adi and methods of use
HK40075284B (zh) 用於癌症治疗的对adi-peg20抗体具有降低的交叉反应性的精氨酸脱亚氨酶
HK40075284A (zh) 用於癌症治疗的对adi-peg20抗体具有降低的交叉反应性的精氨酸脱亚氨酶
HK1219232B (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220315

Address after: Cayman Islands, Grand Cayman

Patentee after: Polaris Pharmaceutical Group Co.,Ltd.

Address before: Ruiguang road Taiwan Taipei City Neihu district China No. 631 4 floor

Patentee before: TDW Group

TR01 Transfer of patent right